

Laura Niccoli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1996838/publications.pdf>

Version: 2024-02-01

16
papers

1,060
citations

949033

11
h-index

1113639

15
g-index

16
all docs

16
docs citations

16
times ranked

2548
citing authors

#	ARTICLE	IF	CITATIONS
1	Tailored first-line biologic and targeted synthetic disease modifying anti-rheumatic drugs therapy in patients with rheumatoid arthritis: 2021 updated ITABIO statements. Expert Opinion on Drug Safety, 2022, 21, 613-623.	1.0	3
2	Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review. Drugs, 2020, 80, 1929-1946.	4.9	74
3	<p>Therapeutic Potential of Ixekizumab in the Treatment of Ankylosing Spondylitis: A Review on the Emerging Clinical Data</p>. Therapeutics and Clinical Risk Management, 2020, Volume 16, 287-297.	0.9	4
4	Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus Kinases. Expert Opinion on Drug Safety, 2020, 19, 861-872.	1.0	24
5	Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study. Journal of Infection, 2020, 81, 647-679.	1.7	155
6	Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. Journal of Infection, 2020, 81, 318-356.	1.7	358
7	The Nocebo Effect in Rheumatology: An Unexplored Issue. Israel Medical Association Journal, 2020, 22, 185-190.	0.1	1
8	Biosimilars for the treatment of psoriatic arthritis. Expert Review of Clinical Immunology, 2019, 15, 1195-1203.	1.3	3
9	Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice. Expert Opinion on Drug Safety, 2019, 18, 415-425.	1.0	33
10	Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs. Expert Review of Anti-Infective Therapy, 2018, 16, 501-512.	2.0	53
11	Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics. Mediators of Inflammation, 2017, 2017, 1-15.	1.4	93
12	Rapid loss of efficacy of biosimilar infliximab in three patients with Behçetâ€™s disease after switching from infliximab originator. European Journal of Rheumatology, 2017, 4, 288-290.	1.3	22
13	Adalimumab, Etanercept, Infliximab, and the Risk of Tuberculosis: Data from Clinical Trials, National Registries, and Postmarketing Surveillance. Journal of rheumatology Supplement, The, 2014, 91, 47-55.	2.2	89
14	Frequency of iridocyclitis in patients with early psoriatic arthritis: a prospective, follow up study. International Journal of Rheumatic Diseases, 2012, 15, 414-418.	0.9	54
15	Psoriatic arthritis: a systematic review. International Journal of Rheumatic Diseases, 2010, 13, 300-317.	0.9	91
16	Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Open Access Rheumatology: Research and Reviews, 2009, 1, 163.	0.8	3